Long-term outcomes of alemtuzumab in relapsing-remitting multiple sclerosis: a real-world cohort with particular focus on treatment sequencing after natalizumab. (PubMed, J Neurol Sci) - Oct 14, 2026 - "In this real-world cohort, alemtuzumab was associated with sustained control of inflammatory disease activity in RRMS, including in patients previously exposed to natalizumab. These findings support a potential role for alemtuzumab within treatment sequencing strategies after NTZ discontinuation."
Journal • Real-world evidence • CNS Disorders • Endocrine Disorders • Immunology • Infectious Disease • Inflammation • Multiple Sclerosis
|
|
Francesca Rinaldi; Giovanni Zanotelli; Marco Puthenparampil; Marco Zoccarato; Marta Gaggiola; Paola Perini; Paolo Gallo; Valentina Annamaria Mauceri
|